Interaction between alpha 5 beta 1 integrin and secreted fibronectin is involved in macrophage differentiation of human HL-60 myeloid leukemia cells.
We examined the role of fibronectin (FN) and FN-binding integrins in macrophage differentiation. Increased FN and alpha5beta1 integrin gene expression was observed in phorbol 12-myristate 13-acetate PMA-treated HL-60 cells and PMA- or macrophage-CSF-treated blood monocytes before the manifestation of macrophage markers. After treatment of HL-60 cells and monocytes, newly synthesized FN was released and deposited on the dishes. An HL-60 cell variant, HL-525, which is deficient in the protein kinase Cbeta (PKC-beta) and resistant to PMA-induced differentiation, failed to express FN after PMA treatment. Transfecting HL-525 cells with a PKC-beta expression plasmid restored PMA-induced FN gene expression and macrophage differentiation. Untreated HL-525 cells (which have a high level of the alpha5beta1 integrin) incubated on FN differentiated into macrophages. The percentage of cells having a macrophage phenotype induced by PMA in HL-60 cells, by FN in HL-525 cells, or by either PMA or macrophage-CSF in monocytes was reduced in the presence of mAbs to FN and alpha5beta1 integrin. The integrin-signaling nonreceptor tyrosine kinase, p72Syk, was activated in PMA-treated HL-60 and FN-treated HL-525 cells. We suggest that macrophage differentiation involves the activation of PKC-beta and expression of extracellular matrix proteins such as FN and the corresponding integrins, alpha5beta1 integrin in particular. The stimulated cells, through the integrins, attach to substrates by binding to the deposited FN. This attachment, in turn, may through integrin signaling activate nonreceptor tyrosine kinases, including p72Syk, and later lead to expression of other genes involved in evoking the macrophage phenotype.
Laouar
A
A
Center for Mechanistic Biology and Biotechnology, Argonne National Laboratory, IL 60439, USA.
Collart
F R
FR
Chubb
C B
CB
Xie
B
B
Huberman
E
E
D002454:Cell Differentiation / Q000187:drug effects / Q000276:immunology; D004789:Enzyme Activation / Q000276:immunology; D004792:Enzyme Precursors / Q000378:metabolism; D005353:Fibronectins / Q000235:genetics / Q000378:metabolism / Q000494:pharmacology / Q000502:physiology*; D015972:Gene Expression Regulation, Neoplastic / Q000276:immunology; D018922:HL-60 Cells; D006801:Humans; D047908:Intracellular Signaling Peptides and Proteins; D007527:Isoenzymes / Q000502:physiology; D015473:Leukemia, Promyelocytic, Acute / Q000235:genetics / Q000276:immunology / Q000473:pathology*; D008264:Macrophages / Q000166:cytology* / Q000187:drug effects / Q000378:metabolism; D011493:Protein Kinase C / Q000502:physiology; D064546:Protein Kinase C beta; D011505:Protein-Tyrosine Kinases / Q000378:metabolism; D017469:Receptors, Fibronectin / Q000502:physiology*; D000072377:Syk Kinase; D013755:Tetradecanoylphorbol Acetate / Q000494:pharmacology; D014407:Tumor Cells, Cultured
D004792:Enzyme Precursors; D005353:Fibronectins; D047908:Intracellular Signaling Peptides and Proteins; D007527:Isoenzymes; D017469:Receptors, Fibronectin; D011505:Protein-Tyrosine Kinases; C000606896:SYK protein, human; D000072377:Syk Kinase; D011493:Protein Kinase C; D064546:Protein Kinase C beta; D013755:Tetradecanoylphorbol Acetate